Jéssica de Jesus

Mrs. Jéssica de Jesus

Faculdade de Medicina da Universidade de São Paulo

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2020 in Pathogens
Verified
Journal Article
Open access
PDF file
Jéssica de JesusJéssica de Jesus
Jéssica de Jesus
TSThays Nicolli Fragoso da Silva
Thays Nicolli Fragoso da Silva
EYEduardo Seiji Yamamoto
Eduardo Seiji Yamamoto
JLJoao Henrique Ghilardi Lago
Joao Henrique Ghilardi Lago
Marcia LaurentiMarcia Laurenti
Marcia Laurenti
Luiz Felipe Domingues PasseroLuiz Felipe Domingues Passero
Luiz Felipe Domingues Passero
Ursolic acid (UA) is a triterpene with a broad array of pharmacological activities. In leishmaniasis, UA killed different species of parasites, and it was active in the experimental model of cutaneous and visceral leishmaniasis. Thus, the objective of this work was to study the therapeutic efficacy of the conventional drugs amphotericin B (AmB) or glucantime (Glu) combined with UA in experimental visceral and cutaneous leishmaniasis, respectively. L. (L.) infantum-infected hamsters were treated with AmB alone or combined with UA. L. (L.) amazonensis-infected BALB/c mice were treated with Glu alone or combined with UA. Animals were treated for 15 consecutive days by intraperitoneal or intralesional routes. Following one week after the last dose, the tissue parasitism and cellular immune responses were analyzed. Hamsters treated with 0.2 and 1.0 mg/kg of AmB plus 1.0 mg/kg of UA showed low hepatic and splenic parasitisms; however, AmB given as monotherapy did not reduce the number of viable parasites in the spleen of treated animals. In cutaneous leishmaniasis, Glu given as monotherapy was inactive at 2.0 mg/kg, showed mild activity at 10.0 mg/kg, and at 50.0 mg/kg was highly active at eliminating parasites in the skin. When animals were treated with Glu plus UA, higher leishmanicidal activity was observed in comparison to all groups treated with monotherapy schemes, and such activity was related to lesion improvement and upregulation of IFN-γ production. Altogether, data suggest that the association of drugs for the treatment of leishmaniasis can increase the efficiency of the treatment and decrease the toxicity associated to the conventional drugs.

31 March 2021 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
ASAdriana Bezerra Souza
Adriana Bezerra Souza
Jéssica de JesusJéssica de Jesus
Jéssica de Jesus
Marcia LaurentiMarcia Laurenti
Marcia Laurenti
Aikaterini LalatsaAikaterini Lalatsa
Aikaterini Lalatsa
DSDolores R Serrano
Dolores R Serrano
Luiz Felipe Domingues PasseroLuiz Felipe Domingues Passero
Luiz Felipe Domingues Passero
The production of ergosterol lipid involves the activity of different enzymes and is a crucial event for the Leishmania membrane homeostasis. Such enzymes can be blocked by azoles and allylamines drugs, such as the antifungal butenafine chloride. This drug was active on parasites that cause cutaneous and visceral leishmaniasis. Based on the leishmanicidal activity of butenafine chloride and considering the absence of reports about the therapeutic potential of this drug in cutaneous leishmaniasis, the present work is aimed at analyzing the efficacy of butenafine formulated in two different topical delivery systems, the self-nanoemulsifying drug delivery systems (BUT-SNEDDS) and in a SNEDDS-based nanogel (BUT-SNEDDS gel) as well as in the free form in experimental cutaneous leishmaniasis. Physical studies showed that both formulations were below 300nm with low polydispersity (0.5) and good colloidal stability (around -25mV). Increased steady-state flux was reported for nanoenabled butenafine formulations with reduced lag time in Franz cell diffusion assays across Strat-M membranes. No toxic or inflammatory reactions were detected in animals treated with BUT-SNEDDS, BUT-SNEDDS gel, or butenafine. Animals topically treated with butenafine (free or nanoformulated) showed small dermal lesions and low tissue parasitism. Furthermore, BUT-SNEDD gel and butenafine presented similar efficacy than the standard drug Glucantime given by the intralesional route. Increased levels of IFN-γ were observed in animals treated with BUT-SNEDDS gel or butenafine. Based on these data, the antifungal drug butenafine chloride can be considered an interesting repurposed drug for the treatment of cutaneous leishmaniasis.

1 December 2017 in Comparative Immunology, Microbiology and Infectious Diseases
Verified
Journal Article
Closed access
Maria Armanda RodriguesMaria Armanda Rodrigues
Maria Armanda Rodrigues
DSD. Santos-Mateus
D. Santos-Mateus
GAG. Alexandre-Pires
G. Alexandre-Pires
ABAna Sofia Valério Bolas
Ana Sofia Valério Bolas
MFMariana Fernandes
Mariana Fernandes
Gabriela Santos-GomesGabriela Santos-Gomes
Gabriela Santos-Gomes

23 November 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Jéssica de JesusJéssica de Jesus
Jéssica de Jesus
TSThays Nicolli Fragoso da Silva
Thays Nicolli Fragoso da Silva
ISIlza Maria Oliveira Sousa
Ilza Maria Oliveira Sousa
AFAurea Favero Ferreira
Aurea Favero Ferreira
Marcia LaurentiMarcia Laurenti
Marcia Laurenti
Luiz Felipe Domingues PasseroLuiz Felipe Domingues Passero
Luiz Felipe Domingues Passero
Leishmaniasis is a neglected tropical disease that affects millions of people around the world. Available therapy causes severe side effects, has unacceptable prices for some specific formulations, and the existence of drug-resistant parasites limits the use of the currently available arsenal of antiparasitic drugs. Therefore, natural products serve as one of the main sources to develop new and effective alternative drugs against leishmaniasis. In this sense, the present study evaluated the potential of the triterpene Lupeol (Lu) entrapped in nanostructured lipid carriers (NLCs) for the treatment of experimental visceral leishmaniasis. The therapeutic efficacy of Lu or Lu entrapped in NLC (Lu-NLC) was investigated in golden hamsters infected with Leishmania (Leishmania) infantum. Lu-NLC presented a mean particle size of 265.3 ± 4.6 nm, a polydispersity index of <0.25 and a zeta potential of −37.2 ± 0.84 mV; the efficacy of encapsulation was 84.04 ± 0.57%. Studies on hamsters showed that Lu-NLC (5 mg/kg) administered intraperitoneally for 10 consecutive days caused a reduction of 99.9% in the number of parasites in the spleen and liver compared to the untreated infected control. On the contrary, Lu-treated animals (5 mg/kg) had 94.4 and 90.2% less parasites in the spleen and liver, respectively, than the infected group. Additionally, a significant preservation of splenic and hepatic tissues was observed in animals treated with Lu-NLC or Lu. Furthermore, Lu-NLC-treated animals produced high levels of anti-Leishmania IgG2 isotype. These data indicate that NLC potentialized Lu efficacy in experimental visceral leishmaniasis. This work suggests that Lu and nanoformulations carrying this compound may be considered as an important tool to be included in the alternative therapy of leishmaniasis.

7 May 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Sarah MelchertSarah Melchert
Sarah Melchert
Jéssica de JesusJéssica de Jesus
Jéssica de Jesus
CRCristiano Raminelli
Cristiano Raminelli
Marcia LaurentiMarcia Laurenti
Marcia Laurenti
Luiz Felipe Domingues PasseroLuiz Felipe Domingues Passero
Luiz Felipe Domingues Passero
Leishmaniasis is a neglected disease caused by protozoa of the genus Leishmania, which causes different clinical manifestations. Drugs currently used in the treatment such as pentavalent antimonial and amphotericin B cause severe side effects in patients, and parasite resistance has been reported. Thus, it is necessary and urgent to characterize new and effective alternative drugs to replace the current chemotherapy of leishmaniasis. In this regard, it has been experimentally demonstrated that quinoline derivatives present significative pharmacological and parasitic properties. Thus, the aim of this work was to demonstrate the leishmanicidal activity of 8-hydroxyquinoline (8-HQ) in vitro and in vivo. The leishmanicidal activity (in vitro) of 8-HQ was assayed on promastigote and intracellular amastigote forms of L. (L.) amazonensis, L. (L.) infantum chagasi, L. (V.) guyanensis L. (V.) naiffi, L. (V.) lainsoni, and L. (V.) shawi. Additionally, the levels of nitric oxide and hydrogen peroxide were analyzed. The therapeutic potential of 8-HQ was analyzed in BALB/c mice infected with a strain of L. (L.) amazonensis that causes anergic cutaneous diffuse leishmaniasis. In vitro data showed that at 24 and 72 h, 8-HQ eliminated promastigote and intracellular amastigote forms of all studied species and this effect may be potentialized by nitric oxide. Furthermore, 8-HQ was more selective than miltefosine. Infected animals treated with 8-HQ by the intralesional route dramatically reduced the number of tissue parasites in the skin, and it was associated with an increase in IFN-γ and decrease in IL-4, which correlated with a reduction in inflammatory reaction in the skin. These results strongly support the idea that 8-HQ is an alternative molecule that can be employed in the treatment of leishmaniasis, given its selectivity and multispectral action in parasites from the Leishmania genus.

1 July 2022 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Jackson MonteiroJackson Monteiro
Jackson Monteiro
Luiz Felipe Domingues PasseroLuiz Felipe Domingues Passero
Luiz Felipe Domingues Passero
Jéssica de JesusJéssica de Jesus
Jéssica de Jesus
Marcia LaurentiMarcia Laurenti
Marcia Laurenti
JLJoão H. G. Lago
João H. G. Lago
PSPatricia Sartorelli
Patricia Sartorelli
Background: The fractionation of the n-hexane phase of the EtOH extract from the leaves of Duguetia lanceolata (Annonaceae) led to the identification of the sesquiterpene (–)-cyclocolorenone. Objectives: Chemical characterization, including determination of the absolute stereochemistry, and in vitro evaluation of antileishmanial activity of the sesquiterpene (–)-cyclocolorenone, isolated from D. lanceolata, were carried out. Methods: (–)-Cyclocolorenone was isolated from D. lanceolata leaves using different chromatographic steps and its structure was defined by analysis of NMR and ESI-HRMS data. Additionally, the absolute configuration of (–)-cyclocolorenone was ambiguously assigned by means of vibrational circular dichroism (VCD). Antileishmanial activity of (–)-cyclocolorenone was evaluated on promastigote and amastigote forms of Leishmania (Leishmania) amazonensis. The integrity of the cell membrane of L. (L.) amazonensis was analyzed using the SYTOX green probe. Results: (–)-(1R,6S,7R,10R)-Cyclocolorenone displayed activity against promastigotes and amastigotes forms of L. (L.) amazonensis with IC50 of 4.54 and 28.44 µM, respectively. Furthermore, this compound was non-toxic in J774 macrophage cells (CC50 > 458.71 µM) with a selectivity index > 100 (promastigotes) and > 32.2 (amastigotes). Additionally, (–)-cyclocolorenone was observed to target the parasite cell membrane. Conclusion: Obtained data suggested that (–)-cyclocolorenone, in which absolute configuration was determined, can be considered as a scaffold for the development of new drugs for the treatment of leishmaniasis.